

## Special Issue

# PROTAC—From Bench to Bed

### Message from the Guest Editors

Proteolysis targeting chimera (PROTAC) technology was developed to artificially induce the degradation of a given protein of interest by hijacking the ubiquitin–proteasome system through a bifunctional molecule. PROTACs were first reported in 2001 and have witnessed rapid development in the past two decades. Many of those bifunctional molecules have been utilized to uncover biology mechanisms as probes, and several Phase I clinical trials have been launched to evaluate the most advanced PROTAC molecules against cancer-related diseases. Compared to traditional small molecules, PROTACs can be more selective with equal potency. However, due to the chemical nature of the protein degrader, achieving molecules with satisfied DMPK properties remains a challenge. This Special Issue will tap into the cutting-edge research development of PROTACs on new targets and PROTACs showing good DMPK properties or animal study results. Biological mechanistic studies using PROTACs as a probe or research studies focusing on PROTAC druggability optimization and pharmacology studies are also welcome.

---

### Guest Editors

Dr. Deyao Li

Memorial Sloan Kettering Cancer Center (MSKCC), 1275 York Ave., New York, NY 10065, USA


Dr. Ke li

Molecular, Cellular and Developmental Biology, Yale University, 260 Whitney Ave., New Haven, CT 06511, USA

---

### Deadline for manuscript submissions

closed (31 January 2023)



## Medicines

---

an Open Access Journal  
by MDPI

---

Indexed in PubMed



[mdpi.com/si/85143](https://mdpi.com/si/85143)

*Medicines*

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland


Tel: +41 61 683 77 34

[medicines@mdpi.com](mailto:medicines@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[medicines](https://medicines)





# Medicines

an Open Access Journal  
by MDPI

Indexed in PubMed



[mdpi.com/journal/  
medicines](https://mdpi.com/journal/medicines)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Hiroshi Sakagami  
Meikai University Research Institute of Odontology (M-RIO), 1-1  
Keyakidai, Sakado, Saitama 350-0283, Japan

---

#### Author Benefits

##### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

##### High Visibility:

indexed within PubMed, PMC, CAPlus / SciFinder, and other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 45 days after submission; acceptance to publication is undertaken in 5.7 days (median values for papers published in this journal in the first half of 2025).